Connect with us

Technology

SOPHiA DDM™ Platform Certified Under IVDR

Published

on

Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets

BOSTON and ROLLE, Switzerland, Aug. 14, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that its SOPHiA DDM™ Platform is now CE marked under the European Union’s In Vitro Diagnostic Regulation (IVDR). IVDR certification is a significant regulatory milestone that validates the powerful analytical capabilities of the SOPHiA DDM™ Platform and allows customers throughout the European Union and other markets recognizing this certification to use the SOPHiA DDM™ Platform to support patient diagnostics.

The transition from the In Vitro Diagnostic Directive (IVDD) to the IVDR in the European Union marks an important advancement in regulatory standards for genetic testing and analysis, including software used for analysis. The new standards promote transparency and traceability throughout genomic analysis processes, helping to ensure the reliability and accuracy of diagnostic results and ultimately patient safety. Users can save time and costs by leveraging an IVDR compliant software platform, like SOPHiA DDM™.

“At SOPHiA GENETICS, certification of our SOPHiA DDM™ Platform under IVDR builds on our track record of offering a broad set of CE-IVD applications and giving our customers confidence in knowing they are using a cutting-edge, compliant Platform for their analysis needs,” said Daan Van Well, LL.M., M.B.A., Chief Legal and Compliance Officer SOPHiA GENETICS. “This was a top priority for our team to ensure a seamless transition for our current CE-IVD customers so they can continue to use the SOPHiA DDM™ Platform to support diagnosis and treatment decisions for patients facing cancer.”

The IVDR registration certifies that the SOPHiA DDM™ Platform’s genetic analysis meets the European IVDR 2017/746 requirements, which govern the sale of in vitro diagnostic devices within the European Economic Area. The SOPHiA DDM™ Platform offers “Dx Mode” in order to satisfy IVDR requirements.

Powered by SOPHiA GENETICS’ proprietary deep learning algorithms, the SOPHiA DDM™ Platform supports state-of-the-art oncology technologies, including five existing CE-IVD SOPHiA DDM™ applications. The Platform uses the collective intelligence gathered by SOPHiA GENETICS’ global network of partners and, to date, has facilitated the analysis of more than 1.7 million genomic profiles.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com and connect on LinkedIn.

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn. 

SOPHiA DDM™ Dx HRD Solution, SOPHiA DDM™ Dx Myeloid Solution, SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx Solid Tumour Solution, and SOPHiA DDM™ Dx RNAtarget Oncology Solution are available as CE-IVD products for In Vitro Diagnostic Use in Europe and Turkey. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-ddm-platform-certified-under-ivdr-302221597.html

SOURCE SOPHiA GENETICS

Continue Reading

Technology

NatGold Digital Announces Immediate Delisting of NATG from MEXC Following U.S. Treasury Action

Published

on

By

CORAL GABLES, Fla., Nov. 7, 2026 /PRNewswire/ — NatGold Digital Ltd. (“NatGold” or the “Company”) today announced that it has requested the delisting of the NatGold Token (NATG) from MEXC, a global cryptocurrency exchange where NATG is currently listed, with immediate effect.

The decision follows the U.S. Department of the Treasury’s announcement of an order issued by its Financial Crimes Enforcement Network (FinCEN) under the Combating Russian Money Laundering Act, prohibiting U.S. financial institutions from processing funds transfers involving MEXC Global.

NatGold is a U.S. company whose wholly owned subsidiary, NatGold Integrity Vault LLC, is registered with FinCEN as a money services business. The Company is acting ahead of the order’s effective date.

“As a U.S. company operating through a FinCEN-registered money services business, we are acting immediately in response to Treasury’s decision,” said Mark Radke, Executive Chairman of NatGold Digital. “Trust is a cornerstone of NatGold’s operating structure, and responding promptly to this regulatory action reflects that commitment.”

NatGold is in advanced discussions with multiple regulatory-compliant exchanges and venues  serving global markets, including the United States, and intends to replace MEXC as soon as possible. Once new listings are confirmed, NATG token holders will be advised of the arrangements and encouraged to register accounts and link their wallets, as applicable, to continue trading.

About NatGold Digital Ltd.

NatGold Digital Ltd. is the global leader in digital gold mining and the architect and operator of a patent-pending, non-extractive platform designed to unlock the intrinsic value of technically verified in-ground gold resources that remain securely stored in Mother Nature’s Vault. NatGold Tokens are structured to represent standardized unit interests in NatGold Certified Resources, disclosed under internationally recognized geological Technical Reports — without physical extraction, processing, or movement of gold. The result is a superior fiat money alternative designed to help lead a global monetary reformation.

For additional background, please visit NatGold.com or our official YouTube channel for videos and information about our digital mining ecosystem: youtube.com/@NatGold_Digital.

Contact

Media@NatGold.com
InvestorServices@NatGold.com
+1 (646) 825-3038

The information in the above release has been prepared by NatGold Digital Ltd. (“NatGold”) using its best efforts to realistically and factually present the information contained herein. However, subjective opinion, reliance on factors outside NatGold’s control, and external information sources unavoidably mean that NatGold cannot warrant the information to be exhaustive, complete, or sufficient. The information provided herein is intended solely for general informational purposes and does not constitute an offer or solicitation for the purchase or sale of any shares or securities of NatGold or for the purchase or sale of any NatGold Tokens. NatGold Tokens are not intended to be “securities” in any jurisdiction, and NatGold makes no claim or representation related to the value of NatGold or NatGold Tokens. Potential investors should seek advice from a qualified financial dealer before investing in NatGold. There are substantial risks associated with investing in development-stage digital assets and technology companies.

View original content to download multimedia:https://www.prnewswire.com/news-releases/natgold-digital-announces-immediate-delisting-of-natg-from-mexc-following-us-treasury-action-302932601.html

SOURCE NatGold Digital Ltd.

Continue Reading

Technology

What to Look for in an Online GLP-1 Provider: Meant Outlines Five Questions Worth Asking Before Signing Up

Published

on

By

MANASSAS, Va., Nov. 7, 2026 /PRNewswire/ — As more telehealth companies offer GLP-1 care, the options can look alike from the outside, and telling them apart takes more than a glance at a landing page. Meant is sharing five questions consumers can ask when choosing an online GLP-1 provider, along with how it approaches each one.

Five Questions Worth Asking

Who makes the clinical decisions? A trustworthy provider should be clear about which licensed clinicians review each person’s information. At Meant, those decisions are made by licensed providers through its clinical partner, OpenLoop Health.Is there a real evaluation first? Look for a health-history review before anything is prescribed, and for plain language that a prescription is never guaranteed. Meant’s online assessment covers health history, current medications, and goals.Can the company’s credentials be checked? Independent certifications are one signal consumers can verify for themselves. Meant displays the seal for its LegitScript certification on its website.Is it clear who fills prescriptions? Providers should be open about the pharmacies they work with and whether those pharmacies are licensed in the United States.Is ongoing support spelled out, limits included? Good providers explain what follow-up looks like and who handles which questions. Meant pairs care with an optional Care Coach, and medical questions go to the care team.

A certification is a transparency signal, not a government approval or a promise about results, and no checklist replaces a conversation with a licensed clinician. Meant does not diagnose or prescribe, and treatment is not guaranteed for every applicant.

Take a Closer Look

Consumers who want to see how the assessment, clinical oversight, and coaching fit together can visit Meant‘s website and compare the details against the questions above.

About Meant

Meant is a health and wellness technology company focused on personalized GLP-1 weight-care support delivered through telehealth. The platform combines an online clinical assessment, licensed oversight through OpenLoop Health, Care Coach support, and supplemental wellness resources. Meant does not itself diagnose or prescribe; clinical decisions are made by its clinical partners. Learn more at meant.health.

Meant Health, Inc.
support@meant.health
1-512-879-9187
10199 Dean Drive, Manassas, VA 20110, USA

View original content:https://www.prnewswire.com/news-releases/what-to-look-for-in-an-online-glp-1-provider-meant-outlines-five-questions-worth-asking-before-signing-up-302927805.html

SOURCE Meant

Continue Reading

Technology

Capturing the Beauty of Anhui through Images–2026 Anhui Photography Season Concludes

Published

on

By

HUANGSHAN, China, Nov. 7, 2026 /PRNewswire/ — A news report from Crionline.

Spanning summer and autumn across three successive photography tours, the “Picturesque Anhui • Imaging Anhui” 2026 Anhui Photography Season officially wrapped up on November 4. Co-hosted by the Fédération Internationale de l’Art Photographique (FIAP), the Anhui Provincial Department of Culture and Tourism, and the Foreign Affairs Office of Anhui Provincial People’s Government, the event drew 116 photographers from 38 countries and regions. They visited 46 distinctive cultural and tourism attractions across five cities: Hefei, Chizhou, Anqing, Huangshan and Xuancheng. Through their lenses, they presented Anhui’s landscapes, cultural heritage and vibrant everyday life to the world.

Looking back on the three sessions: The first session kicked off in Hefei. Photographers documented the city’s innovation-driven urban landscape as well as the picturesque scenery and intangible cultural heritage of Chizhou’s ancient villages. The second session took them deep into Huangshan and Anqing. They explored time-honored Huizhou villages, magnificent mountains and Huangmei Opera culture, immersing themselves in Huizhou traditions and the cultural charm of the Yangtze River region in western Anhui. The concluding third session was held in Huangshan and Xuancheng, focusing on brilliant autumn hues, Huizhou‑style ancient architecture, and the traditional craftsmanship behind the Four Treasures of the Study.

From lush summer greens to rich autumn colours, the photographers produced more than 11,000 high‑resolution photographs. Reflecting the unique perspectives of international participants, these images will be disseminated globally in diverse forms. They will help tell compelling stories of Anhui’s cultural tourism and further boost the province’s international profile.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/capturing-the-beauty-of-anhui-through-images2026-anhui-photography-season-concludes-302932583.html

SOURCE Crionline

Continue Reading

Trending